Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Antiva Biosciences, a US-based developer of treatments for human papillomavirus spun out of University of California, San Diego, has secured $31m in a series D round backed by Osage University Partners. The round included internet and technology group Alphabet and pharmaceutical firms EMS and Dong-A, the first two through GV and Brace Pharma Capital respectively.…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.